Related Experiment Videos
Direct angioplasty versus initial thrombolytic therapy for acute myocardial infarction: long-term follow-up and
J L Vacek1, T L Rosamond, P H Kramer
1Mid-America Heart Institute, St. Luke's Hospital, Kansas City, Missouri.
Insights
For acute myocardial infarction, starting treatment with thrombolytics before angioplasty significantly improves patient survival and reduces adverse events compared to direct angioplasty alone.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Outcomes Research
Background:
- Acute myocardial infarction (AMI) management strategies aim to restore coronary blood flow rapidly.
- Percutaneous coronary intervention (PCI) and thrombolytic therapy are primary reperfusion methods.
- Comparative effectiveness of treatment sequences requires ongoing evaluation.
Purpose of the Study:
- To compare long-term survival and event-free survival in AMI patients treated with direct angioplasty versus thrombolytics followed by angioplasty.
- To analyze outcomes in a recently treated patient cohort to assess current treatment trends.
Main Methods:
- Retrospective analysis of two patient cohorts undergoing AMI treatment.
- Cohort 1: 371 patients with long-term follow-up (mean 3.4 years).
- Cohort 2: 202 patients with short-term follow-up (mean 39 weeks) treated after initial data publication.
Main Results:
- Both 1-year and 2-year survival rates were significantly better (p=0.01, p=0.02) in patients initially treated with thrombolytics.
- Event-free survival (absence of re-infarction, bypass surgery, or repeat angioplasty) was superior (p<0.01) with the thrombolytics-first approach.
- The recently treated cohort also demonstrated improved survival (p=0.002) and event-free survival (p<0.01) with thrombolytics-first treatment.
Conclusions:
- Initial thrombolytic therapy followed by angioplasty offers significant long-term survival and event-free survival benefits for acute myocardial infarction patients.
- These findings support the continued use and potential optimization of a thrombolytics-first reperfusion strategy.
- Differences in baseline characteristics in recent cohorts highlight evolving patient populations and treatment complexities.
Abstract:
We retrospectively studied the outcomes of patients with acute myocardial infarction who were treated with either direct angioplasty or thrombolytics followed by angioplasty. Two patient cohorts were analyzed: a previously reported (in regard to short-term follow-up) group of 371 patients who now have long-term follow-up (mean, 3.4 years) of survival and event-free survival and a second group of 202 patients who have been treated since publication of our initial data. Both 1-year and 2-year survival were significantly better (p = 0.01 and 0.02, respectively) in the group that was treated with thrombolytics first. Event-free survival (i.e., no myocardial infarction, coronary artery bypass graft surgery, repeat angioplasty) was better overall (p < 0.01) for the group that was treated with thrombolytics first. The more recently treated group of patients also showed benefit in regard to both survival (p = 0.002) and event-free survival (p < 0.01) over a short-term follow-up period (mean, 39 weeks) for patients who were treated initially with thrombolytics as compared with those who were treated with direct angioplasty. Although the initial cohort was very similar to the treatment groups except for age (mean age for the direct angioplasty group was 62 +/- 12 years vs 57 +/- 11 years for thrombolytics first group, (p = 0.0002), several differences existed in the more recent treatment groups. The patients who were more recently treated with direct angioplasty were older, had lower mean ejection fraction, had more extensive coronary artery disease, and were more likely to have had prior coronary artery bypass grafting.(ABSTRACT TRUNCATED AT 250 WORDS)